Details of the Drug Combinations

General Information of This Drug (ID: DMTKD7Q)

• Drug Name: BIBW 2992 (DMTKD7Q)
• Synonyms: Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens

Indication

Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Afatinib + DZNep	DC3GYRB	DZNep	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + Buparlisib	DCIFZAP	Buparlisib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + JQ1	DCSP0SS	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + Carfilzomib	DCV15QM	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + Prochlorperazine	DCH5SIZ	Prochlorperazine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + Panobinostat	DCQB1IU	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + CA4P	DCD6E4L	CA4P	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + BMS-754807	DCPEH4J	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + PAC1	DCRAF7O	PAC1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Afatinib + Ruxolitinib	DC3IXTR	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
MK-2206 + Afatinib	DCW4ARR	MK-2206	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Palbociclib + Afatinib	DCAUDSY	Palbociclib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]

15 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Afatinib + Vinorelbine	DCA6MP6	Vinorelbine	Breast Neoplasms	[4]
Afatinib + Afatinib	DCMZGP1	Afatinib	Neoplasms	[5]
Axitinib + Afatinib	DC0JU33	Axitinib	Endometriosis	[6]
Docetaxel + Afatinib	DCENAN5	Docetaxel	Neoplasms	[7]
Gemcitabine + Afatinib	DC5UQR8	Gemcitabine	Neoplasms	[7]
Gemcitabine + Afatinib	DCMI4GF	Gemcitabine	Focus of Study Instead	[8]
Osimertinib + Afatinib	DCW8VJC	Osimertinib	Carcinoma, Non-Small-Cell Lung	[9]
Selumetinib + Afatinib	DCVH7XU	Selumetinib	Colorectal Neoplasms	[10]
Simvastatin + Afatinib	DCZKM1P	Simvastatin	Non-small Cell Lung Cancer	[11]
Talc + Afatinib	DCXO9XE	Talc	Non Small Cell Lung Cancer	[12]
Temozolomide + Afatinib	DCFEBCE	Temozolomide	Glioblastoma	[13]
Erlotinib + Afatinib	DC9DY4O	Erlotinib	Lung Cancer	[14]
Letrozole + Afatinib	DCRF0IM	Letrozole	Breast Neoplasms	[15]
Paclitaxel + Afatinib	DCUV0R0	Paclitaxel	HER-2 Positive Gastric Cancer	[16]
Loperamide + Afatinib	DC7944X	Loperamide	Carcinoma, Non-Small-Cell Lung	[17]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [4] ClinicalTrials.gov (NCT01441596) Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
• [5] ClinicalTrials.gov (NCT01214616) BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
• [6] ClinicalTrials.gov (NCT03481842) Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
• [7] ClinicalTrials.gov (NCT01251653) A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
• [8] ClinicalTrials.gov (NCT01728818) Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours
• [9] ClinicalTrials.gov (NCT03370770) Afatinib Osimertinib Sequencing NIS
• [10] ClinicalTrials.gov (NCT02450656) Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
• [11] ClinicalTrials.gov (NCT01156545) BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
• [12] ClinicalTrials.gov (NCT03827070) Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
• [13] ClinicalTrials.gov (NCT00977431) Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
• [14] ClinicalTrials.gov (NCT02625168) Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
• [15] ClinicalTrials.gov (NCT02115048) Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
• [16] ClinicalTrials.gov (NCT02274012) Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
• [17] ClinicalTrials.gov (NCT01814553) ADAM-Afatinib Diarrhea Assessment and Management